Appointed key leadership to drive (Z)-endoxifen development and evolve pathway to commercialization SEATTLE, /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a ...

Good morning, everyone, and welcome, everyone, to the Prelude Therapeutics Investor Conference Call. Today's call is being recorded and is expected to last up to 45 minutes. At this time, I will now ...

Aethlon Medical, Inc. (the Company or Aethlon) , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results ...

Humacyte, Inc. ( HUMA) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Good morning, ladies and gentlemen, and welcome to the Humacyte's Third Quarter Results Conference Call. [Operator ...

Company reports progress to file planned IND for (Z)-endoxifen in mBC with CRO selection and streamlined development programs for potential 2026-NDA enabling activities ...

This study provides valuable insights into the role of the NF-kB and IKK signaling pathways in γδ T cell development and survival, using robust genetic mouse models. While the research is ...

Replacing APOE4 with APOE2 in adult mice rapidly reshapes brain lipids and gene expression, even after development is ...

The transcription factor HEB synergizes with TCR signaling to upregulate Id3, which is required for the maturation of fetal IL-17-producing γδ T cells.

The investigational, potentially first-in-class agent tinostamustine (EDO-S101) has earned FDA orphan drug designation (ODD) ...

What are the potential health risks of EMF exposure? Read about why more research is urgently needed to better understand the ...